Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annu...( WOODCLIFF LAKE N.J. Oct. 2 /- Dur...),Health

WOODCLIFF LAKE, N.J., Oct. 2 /PRNewswire-FirstCall/ -- Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), announced today the launch of its marketing campaign for ENJUVIA(TM) for the treatment of moderate-to-severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy associated with menopause. ENJUVIA(TM) is the first and only oral estrogen approved by FDA for the treatment of these specific symptoms associated with vaginal atrophy. ENJUVIA, a plant-derived oral estrogen therapy is already approved for the treatment of moderate-to- severe vasomotor symptoms (hot flashes and night sweats) associated with menopause.

The launch of this new indication comes in conjunction with the North American Menopause Society annual meeting, October 3-6.

According to the North American Menopause Society (NAMS), an estimated 10- 40 percent of post-menopausal women suffer from symptoms related to vaginal atrophy (1). Two of the most common symptoms of vaginal atrophy are vaginal dryness and pain with intercourse (2). The symptoms of vaginal atrophy are most commonly associated with the diminished estrogen levels that accompany menopause (1). If left untreated, vaginal atrophy may result in years of discomfort (1).

"ENJUVIA has been shown in clinical studies to provide relief of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy associated with menopause. ENJUVIA's indication for the treatment of these moderate to severe vaginal symptoms associated with menopause affords women and healthcare professionals a new and effective treatment option for two of the most common symptoms associated with vaginal atrophy," stated James A. Simon, M.D., Clinical Professor of Obstetrics and Gynecology at George Washington University and Medical Director, Women's Health & Research Consultants. "There is no one-size-fits-all treatment for menopausal symptoms and wom
'/>"/>